Thomas Steyer’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-16,000
| Closed | -$231K | – | 122 |
|
|
2026
Q1 | $231K | Hold |
16,000
| – | – | ﹤0.01% | 134 |
|
|
2025
Q4 | $228K | Hold |
16,000
| – | – | ﹤0.01% | 128 |
|
|
2025
Q3 | $126K | Hold |
16,000
| – | – | ﹤0.01% | 133 |
|
|
2025
Q2 | $91.7K | Hold |
16,000
| – | – | ﹤0.01% | 133 |
|
|
2025
Q1 | $131K | Hold |
16,000
| – | – | ﹤0.01% | 131 |
|
|
2024
Q4 | $151K | Hold |
16,000
| – | – | ﹤0.01% | 136 |
|
|
2024
Q3 | $171K | Hold |
16,000
| – | – | ﹤0.01% | 146 |
|
|
2024
Q2 | $159K | Hold |
16,000
| – | – | ﹤0.01% | 147 |
|
|
2024
Q1 | $188K | Hold |
16,000
| – | – | ﹤0.01% | 149 |
|
|
2023
Q4 | $227K | Hold |
16,000
| – | – | ﹤0.01% | 122 |
|
|
2023
Q3 | $195K | Buy |
+16,000
| New | +$206K | ﹤0.01% | 131 |
|
|
2021
Q2 | – | Sell |
-100,000
| Closed | -$988K | – | 306 |
|
|
2021
Q1 | $988K | Sell |
100,000
-1,150,000
| -92% | -$17.8M | ﹤0.01% | 227 |
|
|
2020
Q4 | $28.9M | Buy |
+1,250,000
| New | +$25.6M | 0.17% | 82 |
|
|
2018
Q3 | – | Sell |
-3,655,000
| Closed | -$57.1M | – | 105 |
|
|
2018
Q2 | $57.1M | Buy |
3,655,000
+174,000
| +5% | +$2.63M | 0.35% | 47 |
|
|
2018
Q1 | $52.4M | Buy |
3,481,000
+700,000
| +25% | +$10.7M | 0.36% | 48 |
|
|
2017
Q4 | $40M | Sell |
2,781,000
-2,300,055
| -45% | -$31.6M | 0.33% | 44 |
|
|
2017
Q3 | $76.6M | Buy |
5,081,055
+2,081,055
| +69% | +$27.5M | 0.68% | 37 |
|
|
2017
Q2 | $30.2M | Buy |
+3,000,000
| New | +$24.1M | 0.31% | 48 |
|
Other funds holding FOLD
Thomas Steyer's FOLD Position: Q2 2026 in Review
Thomas Steyer sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 16,000 shares — an estimated $231K sold.
Thomas Steyer first reported a position in FOLD in Q2 2017 and held it in 18 quarters. The position peaked at $76.6M in Q3 2017. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Thomas Steyer reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Thomas Steyer sold 16,000 Amicus Therapeutics shares in Q2 2026, an estimated $231K.
- Thomas Steyer first reported a position in Amicus Therapeutics in Q2 2017 and held it in 18 quarters.
- Thomas Steyer's Amicus Therapeutics position peaked at $76.6M in Q3 2017.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.